🇺🇸 FDA
Patent

US 12186282

Treatment of 22Q11.2 deletion syndrome with cannabidiol

granted A61KA61K31/035A61K31/658

Quick answer

US patent 12186282 (Treatment of 22Q11.2 deletion syndrome with cannabidiol) held by Harmony Biosciences Management, Inc. expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Harmony Biosciences Management, Inc.
Grant date
Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/035, A61K31/658, A61K9/0014, A61K9/06